Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis [8]

American Journal of Gastroenterology

Volumn 97, Issue 1, 2002, Pages 209-210

  Okai, Takashi ^a   Mouri, Hisatsugu ^a   Yamaguchi, Yasushi ^a   Nakanuma, Yasuni ^a   Sawabu, Norio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; MITOCHONDRION ANTIBODY; TROGLITAZONE; VOGLIBOSE;

ADULT; BODY MASS; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; LIVER FUNCTION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

EID: 0036142298     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03973-9     Document Type: Letter

References (10)

1. Hepatic dysfunction associated with troglitazone
2. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steato-hepatitis
3. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies
4. In situ detection of lipid peroxidation by-products in chronic liver diseases
5. Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis
6. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes
7. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells
8. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects
9. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
10. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid